Article information
Full text is only aviable in PDF
References
[1.]
A.L. Colombo, T. Guimarães.
Epidemiology of hematogenous infections due to Candida spp.
Rev Soc Bras Med Trop, 36 (2003), pp. 599-607
[2.]
M.C. Dignani, J.S. Solomkin, E. Anaissie.
Candida.
Medical Mycology, 1, pp. 195-239
[3.]
A. Vanden Abbeele, H. de Meel, M. Ahariz, J.P. Perraudin, I. Beyer, P. Courtois.
Denture contamination by yeasts in the elderly.
Gerodontology, 25 (2008), pp. 222-228
[4.]
N.W. Johnson.
The mouth in HIV/AIDS: markers of disease status and management challenges for the dental profession.
Aust Dent J, 55 (2010), pp. 85-102
[5.]
M.A. Kennedy, J.D. Sobel.
Vulvovaginal candidiasis caused by non-albicans Candida species: new insights.
Curr Infect Dis Rep, 12 (2010), pp. 465-470
[6.]
J.M. Achkar, B.C. Fries.
Candida infections of the genitourinary tract.
Clin Microbiol Rev, 23 (2010), pp. 253-273
[7.]
G. Morace, E. Borghi.
Fungal infections in ICU patients: epidemiology and the role of diagnostics.
Minerva Anestesiol, 76 (2010), pp. 950-956
[8.]
S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, R.P. Wenzel.
Hospital acquired candidemia: the attributable mortality and excess length of stay.
Arch Internal Med, 148 (1988), pp. 2642-2645
[9.]
A.L. Colombo, M. Nucci, B.J. Park, et al.
Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.
J Clin Microbiol, 44 (2006), pp. 2816-2823
[10.]
M. Bassetti, E.M. Trecarichi, E. Righi, et al.
Incidence, risk factors and predictors of outcome of candidemia: survey in 2 Italian university hospitals.
Diagn Microbiol Infect Dis, 58 (2007), pp. 325-331
[11.]
D.J. Diekema, S.A. Messer, A.B. Brueggemann, et al.
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.
J Clin Microbiol, 40 (2002), pp. 1298-1302
[12.]
A.L. Colombo, T. Guimarães.
Candiduria: a clinical and therapeutic approach.
Rev Soc Bras Med Trop, 40 (2007), pp. 332-337
[13.]
R.J. Bennett.
A Candida-based view of fungal sex and pathogenesis.
Genome Biol, 10 (2009), pp. 230
[14.]
D.C. Coleman, M.G. Rinaldi, K.A. Haynes, et al.
Importance of Candida species other than Candida albicans as opportunistic pathogens.
Med Mycol, 36 (1998), pp. 156-165
[15.]
A. Tavanti, A.D. Davidson, N.A. Gow, M.C. Maiden, F.C. Odds.
Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.
J Clin Microbiol, 43 (2005), pp. 284-292
[16.]
S.S. Gonçalves, C.S. Amorim, M. Nucci, et al.
Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil.
Clin Microbiol Infect, 16 (2010), pp. 885-887
[17.]
E. Hiller, M. Zavrel, N. Hauser, et al.
Adaptation, adhesion and invasion during interaction of Candida albicans with the host-focus on the function of cell wall proteins.
Int J Med Microbiol, 301 (2011), pp. 384-389
[18.]
R. Ben-Ami, G. Garcia-Effron, R.E. Lewis, et al.
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.
J Infect Dis, 204 (2011), pp. 626-635
[19.]
D. Sanglard, F.C. Odds.
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.
Lancet Infect Dis, 2 (2002), pp. 73-85
[20.]
D. Sullivan, D. Coleman.
Candida dubliniensis: characteristics and identification.
J Clin Microbiol, 36 (1998), pp. 329-334
[21.]
P.L. Mariano, E.P. Milan, D.A. da Matta, A.L. Colombo.
Candida dubliniensis identification in Brazilian yeast stock collection.
Mem Inst Oswaldo Cruz, 98 (2003), pp. 533-538
[22.]
V. Krcmery, A.J. Barnes.
Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance.
J Hosp Infect, 50 (2002), pp. 243-260
[23.]
P. Godoy, I.N. Tiraboschi, L.C. Severo, et al.
Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals.
Mem Instit Oswaldo Cruz, 98 (2003), pp. 401-405
[24.]
M.A. Pfaller.
Nosocomial candidiasis: emerging species, reservoirs and modes of transmission.
Clin Infect Dis, 22 (1996), pp. S89-S94
[25.]
A.L. Colombo, T. Guimarães, L.R. Silva, et al.
Prospective observational study of candidemia in São Paulo Brazil: incidence rate, epidemiology, and predictors of mortality.
Infect Control Hosp Epidemiol, 28 (2007), pp. 570-576
[26.]
S.F. Costa, I. Marinho, E.A. Araújo, A.E. Manrique, E.A.S. Medeiros, A.S. Levin.
Nosocomial fungaemia: a 2-year prospective study.
J Hosp Infect, 45 (2000), pp. 69-72
[27.]
A.S. Levin, S.F. Costa, N.S. Mussi, et al.
Candida parapsilosis fungemia associated with implantable and semiimplantable central venous catheters and the hands of health care workers.
Diagn Microbiol Infect Dis, 30 (1998), pp. 243-249
[28.]
M.A. Pfaller, S.A. Messer, G.J. Moet, R.N. Jones, M. Castanheira.
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENT RY Antimicrobial Surveillance Program (2008–2009).
Int J Antimicrob Agents, 38 (2011), pp. 65-69
[29.]
M.A. Pfaller, D.J. Diekema, L. Ostrosky-Zeichner, et al.
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol, 46 (2008), pp. 2620-2629
[30.]
J. Mora-Duarte, R. Betts, C. Rotstein, et al.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med, 347 (2002), pp. 2020-2029
[31.]
E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, et al.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Lancet, 369 (2007), pp. 1519-1527
[32.]
A.C. Reboli, C. Rotstein, P.G. Pappas, et al.
Anidulafungin versus fluconazole for invasive candidiasis.
N Engl J Med, 356 (2007), pp. 2472-2482
[33.]
D.P. Kofteridis, R.E. Lewis, D.P. Kontoyiannis.
Caspofungin-nonsusceptible Candida isolates in cancer patients.
J Antimicrob Chemother, 65 (2010), pp. 293-295
[34.]
A.L. Colombo, A.L. Ngai, M. Bourque, et al.
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Antimicrob Agents Chemother, 54 (2010), pp. 1864-1871
[35.]
P.B. Kale-Pradhan, G. Morgan, S.M. Wilhelm, L.B. Johnson.
Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Pharmacotherapy, 30 (2010), pp. 1207-1213
[36.]
A.S. Melo, F.C. Bizerra, E. Freymüller, B.A. Arthington-Skaggs, A.L. Colombo.
Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex.
Med Mycol, 49 (2011), pp. 253-262
[37.]
J.R. Wingard.
Importance of Candida species other than C. albicans as pathogens in oncology patients.
Clin Infect Dis, 20 (1995), pp. 115-125
[38.]
A.L. Colombo, M. Nucci, R. Salomão, et al.
High rate of nonalbicans candidemia in Brazilian tertiary care hospitals.
Diagn Microbiol Infect Dis, 34 (1999), pp. 281-286
[39.]
L.Z. Goldani, P.S. Mario.
Candida tropicalis fungemia in a tertiary care hospital.
J Infect, 46 (2003), pp. 150-160
[40.]
S. Alp, B. Sancak, G. Hascelik, S. Arikan.
Influence of different susceptibility testing methods and media on determination of the relevant fluconazole minimum inhibitory concentrations for heavy trailing Candida isolates with low-high phenotype.
Mycoses, 53 (2010), pp. 475-480
[41.]
D. Abi-Said, E. Anaissie, O. Uzun, H. Pinzcowski, S. Vartivarian.
The epidemiology of hematogenous candidiasis caused by different Candida species.
Clin Infect Dis, 24 (1997), pp. 1122-1128
[42.]
M. Nucci, F. Queiroz-Telles, A.M. Tobón, A. Restrepo, A.L. Colombo.
Epidemiology of opportunistic fungal infections in Latin America.
Clin Infect Dis, 51 (2010), pp. 561-570
[43.]
T.Z. Sampaio Camargo, A.R. Marra, et al.
Secular trends of candidemia in a tertiary care hospital.
Am J Infect Control, 38 (2010), pp. 546-551
[44.]
M.A. Pfaller, D.J. Diekema, R.N. Jones, SENTRY Participant Group, et al.
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENT RY antimicrobial surveillance program.
J Clin Microbiol, 39 (2001), pp. 3254-3259
[45.]
D.B. Safran, E. Dawson.
The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit.
Arch Surg, 132 (1997), pp. 1184-1188
[46.]
M.A. Pfaller, S.A. Messer, L. Boyken, S. Tendolkar, R.J. Hollis, D.J. Diekema.
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
J Clin Microbiol, 42 (2004), pp. 3142-3146
[47.]
D.J. Diekema, M.A. Pfaller, R.N. Jones.
Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America SENT RY Antimicrobial Surveillance Program, 1997–2000.
Int J Antimicrob Agents, 20 (2002), pp. 412-418
[48.]
P.C. Iwen, D.M. Kelly, E.C. Reed, S.H. Hinrichs.
Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole.
Clin Infect Dis, 20 (1995), pp. 342-347
[49.]
M. Drago, M.M. Scaltrito, G. Morace.
In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 619-624
[50.]
C. Girmenia, G. Pizzarelli, F. Cristini, et al.
Candida guilliermondii fungemia in patients with hematologic malignancies.
J Clin Microbiol, 44 (2006), pp. 2458-2464
[52.]
W.G. Merz.
Candida lusitaniae: frequency of recovery, colonization, infection and amphotericin B resistance.
J Clin Microbiol, 20 (1984), pp. 1194-1195
[53.]
D.J. Hata, L. Hall, A.W. Fothergill, D.H. Larone, N.L. Wengenack.
Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card.
J Clin Microbiol, 45 (2007), pp. 1087-1092
[54.]
G. Forrest.
Role of antifungal susceptibility testing in patient management.
Curr Opin Infect Dis, 19 (2006), pp. 538-543
[55.]
S. Perkhofer, C. Mrazek, L. Hartl, C. Lass-Flörl.
In vitro susceptibility testing in Fungi: what is its role in clinical practice?.
Curr Infect Dis Rep, 12 (2010), pp. 401-408
[56.]
C. Traeder, S. Kowoll, K. Arastéh.
Candida infection in HIV positive patients 1985–2007.
Mycoses, 51 (2008), pp. 58-61
[57.]
Clinical and Laboratory Standards Institute (CLSI). Reference Method for broth dilution antifungal susceptibility testing of yeasts. Document M27-A3. 3rd ed. 2008;28(14):1–7.
[58.]
Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405.
[59.]
C. Farina, E. Manso, S. Andreoni, et al.
Interlaboratory evaluation of VITEK-2 system and Sensititre YeastOne® for antifungal susceptibility testing of yeasts isolated from blood cultures against four antifungal agents.
New Microbiol, 34 (2011), pp. 195-201
[60.]
M. Cuenca-Estrella, J.L. Rodriguez-Tudela.
The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.
Expert Rev Anti Infect Ther, 8 (2010), pp. 267-276
[61.]
M. Baginski, J. Czub.
Amphotericin B and its new derivatives - mode of action.
Curr Drug Metab, 10 (2009), pp. 459-469
[62.]
R. Laniado-Laborín, M.N. Cabrales-Vargas.
Amphotericin B: side effects and toxicity.
Rev Iberoam Micol, 26 (2009), pp. 223-227
[63.]
M.J. Rüping, J.J. Vehreschild, O.A. Cornely.
Antifungal treatment strategies in high risk patients.
Mycoses, 51 (2008), pp. 46-51
[64.]
J.R. Wingard, M.H. White, E. Anaissie, J. Raffalli, J. Goodman, A. Arrieta, L Amph/ABLC Collaborative Study Group.
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia L Amph/ABLC Collaborative Study Group.
Clin Infect Dis, 31 (2000), pp. 1155-1163
[65.]
A. Safdar, J. Ma, F. Saliba, et al.
Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.
Medicine (Baltimore), 89 (2010), pp. 236-244
[66.]
A.H. Groll, T.J. Walsh.
Uncommon opportunistic fungi: new nosocomial threats.
Clin Microbiol Infect, 7 (2001), pp. 8-24
[67.]
P.G. Pappas.
Invasive Candidiasis.
Infect Dis Clin N Am, 20 (2006), pp. 485-506
[68.]
J.A. Maertens.
History of the development of azole derivatives.
Clin Microbiol Infect, 10 (2004), pp. 1-10
[69.]
J.A. Como, W.E. Dismukes.
Oral azole drugs as systemic antifungal therapy.
N Engl J Med, 330 (1994), pp. 263-272
[70.]
J. Heeres, L. Meerpoel, P. Lewi.
Conazoles.
Molecules, 15 (2010), pp. 4129-4188
[71.]
G. Aperis, E. Mylonakis.
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
Expert Opin Investig Drugs, 15 (2006), pp. 579-602
[72.]
M.A. Pfaller, A. Espinel-Ingroff, L. Boyken, et al.
Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
J Clin Microbiol, 49 (2011), pp. 845-850
[73.]
M.C. Arendrup.
Epidemiology of invasive candidiasis.
Curr Opin Crit Care, 16 (2010), pp. 445-452
[74.]
J. Wheat, G. Sarosi, D. McKinsey, et al.
Practice guidelines for the management of patients with histoplasmosis Infectious Diseases Society of America.
Clin Infect Dis, 30 (2000), pp. 688-695
[75.]
M.A. Shikanai-Yasuda, Q. Telles Filho Fde, R.P. Mendes, A.L. Colombo, M.L. Moretti.
[Guidelines in paracoccidioidomycosis].
Rev Soc Bras Med Trop, 39 (2006), pp. 297-310
[76.]
A. De Sarro, E. La Camera, M.T. Fera.
New and investigational triazole agents for the treatment of invasive fungal infections.
J Chemother, 20 (2008), pp. 661-671
[77.]
C. Charlier, E. Hart, A. Lefort, et al.
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?.
J Antimicrob Chemother, 57 (2006), pp. 384-410
[78.]
K.L. Goa, L.B. Barradell.
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Drugs, 50 (1995), pp. 658-690
[79.]
L.J. Scott, D. Simpson.
Voriconazole: a review of its use in the management of invasive fungal infections.
Drugs, 67 (2007), pp. 269-298
[80.]
T.J. Walsh, E.J. Anaissie, D.W. Denning, et al.
Infectious Diseases Society of America Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clin Infect Dis, 46 (2008), pp. 327-360
[81.]
B.J. Kullberg, J.D. Sobel, M. Ruhnke, et al.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Lancet, 366 (2005), pp. 1435-1442
[82.]
A.K. Mehta, A.A. Langston.
Use of posaconazole in the treatment of invasive fungal infections.
Expert Rev Hematol, 2 (2009), pp. 619-630
[83.]
A.J. Sucher, E.B. Chahine, H.E. Balcer.
Echinocandins: the newest class of antifungals.
Ann Pharmacother, 43 (2009), pp. 1647-1657
[84.]
W.W. Hope, S. Shoham, T.J. Walsh.
The pharmacology and clinical use of caspofungin.
Expert Opin Drug Metab Toxicol, 3 (2007), pp. 263-274
[85.]
B.T. Fisher, T. Zaoutis.
Caspofungin for the treatment of pediatric fungal infections.
Pediatr Infect Dis J, 27 (2008), pp. 1099-1102
[86.]
K.P. Garnock-Jones, S.J. Keam.
Caspofungin: in pediatric patients with fungal infections.
Paediatr Drugs, 11 (2009), pp. 259-269
[87.]
T. Lehrnbecher, A.H. Groll.
Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
Pediatr Blood Cancer, 55 (2010), pp. 229-232
[88.]
F. Menichetti.
Anidulafungin, a new echinocandin: effectiveness and tolerability.
Drugs, 69 (2009), pp. 95-97
[89.]
P.G. Pappas, C.M. Rotstein, R.F. Betts, et al.
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Clin Infect Dis, 45 (2007), pp. 883-893
[90.]
Z. Temesgen, J. Barreto, S. Vento.
Micafungin - the newest echinocandin.
Drugs Today (Barc), 45 (2009), pp. 469-478
[91.]
Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121:1193–254.
[92.]
J.A. Vazquez, J.D. Sobel.
Mucosal candidiasis.
Infect Dis Clin North Am, 16 (2002), pp. 793-820
[93.]
N. Weerasuriya, J. Snape.
A study of Candida esophagitis in elderly patients attending a district general hospital in the UK.
Dis Esophagus, 19 (2006), pp. 189-192
[95.]
J.A. Vazquez.
Invasive oroesophageal candidiasis: current and developing treatment options.
Drugs, 63 (2003), pp. 971-989
[96.]
M. Goldman, G.A. Cloud, K.D. Wade, et al.
AIDS Clinical Trials Group Study Team 323; Mycoses Study Group Study Team 40. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Clin Infect Dis, 41 (2005), pp. 1473-1480
[97.]
J.A. Underwood, J.W. Williams, R.F. Keate.
Clinical findings and risk factors for Candida esophagitis in outpatients.
Dis Esophagus, 16 (2003), pp. 66-69
[98.]
A.N. Ellepola, L.P. Samaranayake.
Oral candidal infections and antimycotics.
Crit Rev Oral Biol Med, 11 (2000), pp. 172-198
[99.]
J.S. Golub, M.M. Johns 3rd..
Esophageal candidiasis.
Ear Nose Throat J, 84 (2005), pp. 765
[100.]
R. Cha, J.D. Sobel.
Fluconazole for the treatment of candidiasis: 15 years experience.
Expert Rev Anti Infect Ther, 2 (2004), pp. 357-366
[101.]
K. Thom, G. Forrest.
Gastrointestinal infections in immunocompromised hosts.
Curr Opin Gastroenterol, 22 (2006), pp. 18-23
[102.]
P.G. Pappas, C.A. Kauffman, D. Andes, et al.
Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis, 48 (2009), pp. 503-535
[103.]
G. Barbaro, G. Barbarini, G. Di Lorenzo.
Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study.
Scand J Infect Dis, 27 (1995), pp. 613-617
[104.]
F. Queiroz-Telles, N. Silva, M.M. Carvalho, et al.
Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in Aids patients.
Braz J Infect Dis, 5 (2001), pp. 60-66
[105.]
R. Ally, D. Schurmann, W. Kreisel, et al.
A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Clin Infect Dis, 33 (2001), pp. 1447-1454
[106.]
J.A. Vasquez, D.J. Skiest, L. Nieto, et al.
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Clin Infect Dis, 42 (2006), pp. 1179-1186
[107.]
D.J. Skiest, J.A. Vazquez, G.M. Anstead, et al.
Posaconazole for the treatment of azole refractory oropharyngeal and esophageal candidiasis in subjects with HIV infections.
Clin Infect Dis, 44 (2007), pp. 607-614
[108.]
P.M. Finlay, M.D. Richardson, A.G. Robertson.
A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours.
Br J Oral Maxillofac Surg, 34 (1996), pp. 23-25
[109.]
A. Villanueva, E. Gotuzzo, E.G. Arathoon, et al.
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Am J Med, 113 (2002), pp. 294-299
[110.]
D.S. Krause, A.E. Simjee, C. van Rensburg, et al.
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Clin Infect Dis, 39 (2004), pp. 770-775
[111.]
N. deWet, A. Llanos-Cuentas, J. Suleiman, et al.
A randomized, doubleblind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIVpositive patients.
Clin Infect Dis, 39 (2004), pp. 842-849
[112.]
P. Giraldo, S. Witkin.
Vaginal candidiasis: an incompreehensible challenge.
I Bras Dis Sex Transm, 10 (1998), pp. 31-36
[113.]
A. Holanda, A. Fernandes, C. Bezerra, E. Milan.
Candidíase vulvovaginal: uma revisão de literatura.
Femina, 33 (2005), pp. 347-351
[114.]
D. Novawack, F. Lara.
Estudo dos aspectos clínicos, epidemiológicos e atualização terapêutica das vulvovaginites por Candida sp, Trichomonas vaginalis e vaginoses bacterianas por Gardnerella vaginalis.
JBM, 77 (1999), pp. 46-50
[115.]
L. Galle, M. Gianinni.
Prevalência e susceptibilidade de leveduras vaginais.
J Bras Patol Med Lab, 40 (2004), pp. 229-236
[116.]
J.D. Sobel.
Pathogenesis and treatment of recurrent vulvovaginal candidiasis.
Clin Infect Dis, 14 (1992), pp. S148-S153
[117.]
J.D. Sobel.
Vulvovaginal candidosis.
Lancet, 369 (2007), pp. 1961-1971
[118.]
M. Costa, O. Fernandes, M. Silva.
Candidíase vulvovaginal: aspectos clínicos, tratamento oral com azólicos e suscetibilidade in vitro.
Revista de Patologia Tropical, 32 (2003), pp. 145-162
[119.]
M.C. Watson, J.M. Grimshaw, C.M. Bond, J. Mollison, A. Ludbrook.
Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review.
Bjog, 109 (2002), pp. 85-95
[120.]
M. Urunsak, M. Ilkit, C. Euruke, I. Urunsak.
Clinical and mycological efficacy of single-day oral treatment with itraconazole (400mg) in acute vulvovaginal candidosis.
Mycoses, 47 (2004), pp. 422-427
[121.]
A.W. Kimberly, M.B. Stuart.
Sexually transmitted diseases treatment guidelines 2006.
MMWR, 55 (2006), pp. 1-54
[122.]
J.D. Sobel, H.C. Wiesenfeld, M. Martens, et al.
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
N Engl J Med, 351 (2004), pp. 876-883
[123.]
I.W. Fong.
The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis.
Genitourin Med, 68 (1992), pp. 374-377
[124.]
A. Witt, U. Kaufmann, M. Bitschnau, et al.
Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial.
BJOG, 116 (2009), pp. 1499-1505
[125.]
D. Ray, R. Goswami, U. Banerjee, et al.
Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Diabetes Care, 30 (2007), pp. 312-317
[126.]
F. Alvarez-Lerma, J. Nolla-Salas, C. Leon, et al.
Candiduria in critically ill patients admitted to intensive care medical units.
Intensive Care Medicine, 29 (2003), pp. 1069-1076
[127.]
C.A. Kauffman.
Candiduria.
Clin Infect Dis, 41 (2005), pp. S371-S376
[128.]
J.D. Sobel, J.F. Fisher, C.A. Kauffman, C.A. Newman.
Candida urinary tract infections-epidemiology.
Clin Infect Dis, 52 (2011), pp. S433-S436
[129.]
M. Nucci.
Candiduria in hospitalized patients: a review.
Braz J Infect Dis, 4 (2000), pp. 168-172
[130.]
R.D. Oliveira, C.M. Maffei, R. Martinez.
Nosocomial urinary tract infections by Candida species.
Rev Assoc Med Bras, 47 (2001), pp. 231-235
[131.]
C.C. Kobayashi, O.F. De Fernandes, K.C. Miranda, E.D. De Sousa, R. Silva Mdo.
Candiduria in hospital patients: a study prospective.
Mycopathologia, 158 (2004), pp. 49-52
[132.]
X.S. Passos, W.S. Sales, P.J. Maciel, et al.
Candida colonization in intensive care unit patients’ urine.
Memórias do Instituto Oswaldo Cruz, 100 (2005), pp. 925-928
[133.]
A.L. Colombo, T. Guimarães.
Candiduria: a clinical and therapeutic approach.
Rev Soc Bras Med Trop, 40 (2007), pp. 332-337
[134.]
J.D. Sobel.
Controversies in the diagnosis of candiduria: what is the critical colony count.
Curr Treat Options Infect Dis, 4 (2002), pp. 81-83
[135.]
J.F. Fisher, C.L. Newman, J.D. Sobel.
Yeasts in the urine: solutions for a budding problem.
Clin Infect Dis, 20 (1995), pp. 183-189
[136.]
B.S.P. Ang, A. Telenti, B. King, J.M. Steckalberg, W.D. Wilson.
Candidemia from urinary tract source: microbiological aspects and clinical significance.
Clin Infect Dis, 17 (1993), pp. 622-627
[137.]
T. Lundstrom, J. Sobel.
Nosocomial candiduria: a review.
Clin Infect Dis, 32 (2001), pp. 1602-1607
[138.]
J.D. Sobel, C.A. Kauffman, D. McKinsey, et al.
Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo.
Clin Infect Dis, 30 (2000), pp. 19-24
[139.]
P. Fan-Havard, C. O’Donovan, S.M. Smith, J. Oh, M. Bamberger, R.H.K. Eng.
Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria.
Clin Infect Dis, 21 (1995), pp. 960-965
[140.]
J.F. Fisher, J.D. Sobel, C.A. Kauffman, C.A. Newman.
Candida urinary tract infections-treatment.
Clin Infect Dis, 52 (2011), pp. S457-S466
[141.]
J.R. Johnson.
Should all catheterized patients with candiduria be treated?.
Clin Infect Dis, 17 (1993), pp. 814
[142.]
E. Bibashi, D. Memmos, E. Kokolina, et al.
Fungal peritonitis complicating peritoneal dialysis during an 11-year period: report of 46 cases.
Clin Infec Dis, 36 (2003), pp. 927-931
[143.]
N.R. Powe.
Septicemia in dialysis patients: incidence, risk factors and prognosis.
Kidney International, 55 (1999), pp. 1081-1090
[144.]
K.H. Chen, C.T. Chang, C.C. Yu, et al.
Candida parapsilosis peritonitis has more complications than other Candida peritonitis in peritoneal dialysis patients.
Renal Failure, 28 (2006), pp. 241-246
[145.]
A.Y. Wang, A.W. Yu, P.K. Li, et al.
Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center.
Am J Kidney Dis, 36 (2000), pp. 1183-1192
[146.]
N. Prasad, A. Gupta.
Fungal peritonitis in peritoneal dialysis patients.
Perit Dial Int, 25 (2005), pp. 207-222
[147.]
J. Matuszkiewicz-Rowinska.
Update on fungal peritonitis and its treatment.
Perit Dial Int, 29 (2009), pp. S161-S165
[148.]
H. Kameoka, K. Kumakawa, T. Matuoka, M. Nakano, Y. Shiraiwa, O. Yamaguchi.
Intraperitoneal fluconazole for fungal peritonitis in CAPD: report of two cases.
Perit Dial Int, 19 (1999), pp. 481-483
[149.]
P.N. Wong, K.Y. Lo, G.M. Tong, S.F. Chan, M.W. Lo, S.K. Mak, A.K. Wong.
Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine and delayed catheter replacement in continuous ambulatory peritoneal dialysis.
Perit Dial Int, 28 (2008), pp. 155-162
[150.]
O.A. Cornely, M. Lasso, R. Betts, et al.
Caspofungin for the treatment of less common forms of invasive candidiasis.
J Antimicrob Chemother, 60 (2007), pp. 363-369
[151.]
P. Sandven, H. Qvist, E. Skovlund, K.E. Giercksky, NO RGAS Group and the Norwegian Yeast Study Group.
Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations.
Crit Care Med, 30 (2002), pp. 541-547
[152.]
T. Calandra, J. Bille, R. Schneider, F. Mosimann, P. Francioli.
Clinical significance of Candida isolated from peritoneum in surgical patients.
Lancet, 2 (1989), pp. 1437-1440
[153.]
P. Montravers, H. Dupont, R. Gauzit, et al.
Candida as a risk factor for mortality in peritonitis.
Crit Care Med, 34 (2006), pp. 646-652
[154.]
J.S. Solomkin, J.E. Mazuski, J.S. Bradley, et al.
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.
Clin Infect Dis, 50 (2010), pp. 133-164
[155.]
I. Stijn, B. Blota, H. Koenraad, B. Vandewoudea, J. Jan.
Candida peritonitis.
Curr Opinion Crit Care, 13 (2007), pp. 195-199
[156.]
E. Azoulay, Y. Cohen, J.R. Zahar, et al.
Practices in nonneutropenic ICU patients with Candida-positive airway specimens.
Intensive Care Med, 30 (2004), pp. 1384-1389
[157.]
D.R. Nunley, A.A. Gal, J.D. Vega, C. Perlino, P. Smith, E.C. Lawrence.
Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation.
Chest, 122 (2002), pp. 1185-1191
[158.]
M. El-Ebiary, A. Torres, N. Fabregas.
Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients An immediate postmortem histologic study.
Am J Respir Crit Care Med, 156 (1997), pp. 583
[159.]
F. Alvarez-Lerma, M. Palomar, C. Leon, P. Olaechea, E. Cerda, B. Bermejo.
Grupo de Estudio de Infecion Fungica Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients.
Med Clin (Barc), 121 (2003), pp. 161-166
[160.]
D.P. Kontoyiannis, B.T. Reddy, H.A. Torres, et al.
Pulmonary candidiasis in patients with cancer: an autopsy study.
Clin Infect Dis, 34 (2002), pp. 400-403
[161.]
T. Franquet, N.L. Muller, K.S. Lee, A. Oikonomou, J.D. Flint.
Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings.
Radiology, 236 (2005), pp. 332-337
[162.]
F. Oner-Eyuboglu, O. Karacan, S. Akcay, H. Arslan, B. Demirhan, M. Haberal.
Invasive pulmonary fungal infections in solid organ transplant recipients: a four-year review.
Transplant Proc, 35 (2003), pp. 2689-2691
[163.]
H. Yamada, H. Kotaki, T. Takahashi.
Recommendations for the treatment of fungal pneumonias.
Expert Opin Pharmacother, 4 (2003), pp. 1241-1258
[164.]
G.T. Cole, A.A. Halawa, E.J. Anaisse.
The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside.
Clin Infect Dis, 22 (1996), pp. 73-88
[165.]
J.W. Alexander, S.T. Boyce, G.F. Babcock.
The process of microbial translocation.
Annals of Surgery, 212 (1990), pp. 496-510
[166.]
M.A. Pfaller.
Nosocomial candidiasis: emerging species, reservoirs and modes of transmission.
Clin Infect Dis, 22 (1996), pp. S89-S94
[167.]
F.M.V. Lunel, J.F.G.M. Meis, A. Voss.
Nosocomial fungal infections: candidemia.
Diagn Microbiol Infect Dis, 34 (1999), pp. 213-220
[168.]
S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, R.P. Wenzel.
Hospital acquired candidemia The attributable mortality and excess length of stay.
Arch Int Med, 148 (1988), pp. 2642-2645
[169.]
A.L. Colombo, J. Perfect, M. DiNubile, et al.
Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Eur J Clin Microbiol Infect Dis, 22 (2003), pp. 470-474
[170.]
A.C. Pasqualotto, R.A. Zimerman, S.H. Alves, V.R. Aquino, D. Branco, D. Wiltgen, A. do Amaral, R. Cechinel, S.M. Colares, I.G. da Rocha, L.C. Severo, T.C. Sukiennik.
Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.
Infect Control Hosp Epidemiol, 29 (2008), pp. 898-899
[171.]
C.H. Debusk, R. Daoud, M.C. Thirumoorthi, F.M. Wilson, R. Khatib.
Candidemia: current epidemiologic characteristics and a longterm follow-up of the survivors.
Scand J Infect Dis, 26 (1994), pp. 697-703
[172.]
J. Kriengkauykiat, J.I. Ito, S.S. Dadwal.
Epidemiology and treatment approaches in management of invasive fungal infections.
Clin Epidemiol, 3 (2011), pp. 175-191
[173.]
G.P. Bodey, M. Luna.
Skin lesions associated with disseminated candidiasis.
JAMA, 229 (1974), pp. 1466-1468
[174.]
L.J. Rodriguez-Adrian, R.T. King, L.G. Tamayo-Derat, J.W. Miller, C.A. Garcia, J.H. Rex.
Retinal lesions as clues to disseminated bacterial and candidal infections: Frequency, natural history, and etiology.
Medicine (Baltimore), 82 (2003), pp. 187-202
[175.]
A.M. Oude Lashof, A. Rothova, J.D. Sobel, et al.
Ocular manifestations of candidemia.
Clin Infect Dis, 53 (2011), pp. 262-268
[176.]
R. Krishna, D. Amuh, C.Y. Lowder, S.M. Gordon, K.A. Adal, G. Hall.
Should all patients with candidemia have an ophthalmic examination to rule out ocular candidiasis?.
Eye, 14 (2000), pp. 30-34
[177.]
S.G. Filler, B.J. Kullberg.
Deep-seated candidal infections.
Medical Mycology, 1, pp. 341-348
[178.]
M.W. Donnino, N. Goyal, T.M. Terlecki, et al.
Inadequate blood volume collected for culture: a survey of health care professionals.
Mayo Clin Proc, 82 (2007), pp. 1069-1072
[179.]
L.L. Horvath, B.J. George, D.R. Hospenthal.
Detection of fifteen species of Candida in an automated blood culture system.
J Clin Microbiol, 45 (2007), pp. 3062-3064
[180.]
A. Masood, S. Sallah.
Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment.
Leuk Research, 29 (2005), pp. 493-501
[181.]
B. Almirante, M. Cuenca-Estrella.
Candidemia: impact of epidemiological studies on the treatment and prognosis of a serious infection.
Enferm Infecc Microbiol Clin, 29 (2011), pp. 325-327
[182.]
A.L. Motta, G.M. Almeida, J.N. Almeida Júnior, M.N. Burattini, F. Rossi.
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex.
Braz J Infect Dis, 14 (2010), pp. 441-448
[183.]
D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, J.H. Rex, J.D. Sobel, P.G. Pappas, B.J. Kullberg, for the Mycoses Study Group.
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials.
Clin Infect Dis, 54 (2012), pp. 1110-1122
[184.]
J.H. Rex, P.G. Pappas, A.W. Karchmer, et al.
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
Clin Infect Dis, 36 (2003), pp. 1221-1228
[185.]
D.W. Bates, L. Su, D.T. Yu, et al.
Mortality and costs of acute renal failure associated with amphotericin B therapy.
Clin Infect Dis, 32 (2001), pp. 686-693
[186.]
J.H. Rex, J.E. Bennett, A.M. Sugar, et al.
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia Candidemia Study Group and the National Institute.
N Engl J Med, 331 (1994), pp. 1325-1330
[187.]
S. Sallah, R.C. Semelka, W. Sallah, J.R. Vainright, D.L. Philips.
Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis.
Leuk Res, 23 (1999), pp. 995-999
[188.]
W.T. Hughes, D. Armstrong, G.P. Bodey, et al.
2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Clin Infect Dis, 34 (2002), pp. 730-751
[189.]
T.J. Walsh, H. Teppler, G.R. Donowitz, et al.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
N Engl J Med, 351 (2004), pp. 1391-1402
[190.]
M. Corey.
Modern antifungal therapy for neutropenic fever.
Curr Infect Dis Rep, 11 (2009), pp. 29-34
[191.]
M.A. Slavin, T.C. Sorrell, D. Marriott, et al.
Australian Candidemia Study Australasian Society for Infectious Diseases. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
J Antimicrob Chemother, 65 (2010), pp. 1042-1051
[192.]
F. Riddell 4th, G.M. Comer, C.A. Kauffman.
Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.
Clin Infect Dis, 52 (2011), pp. 648-653
[193.]
M.E. Akler, H. Vellend, D.M. McNeely, S.L. Walmsley, W.L. Gold.
Use of fluconazole in the treatment of candidal endophthalmitis.
Clin Infect Dis, 20 (1995), pp. 657-664
[194.]
D.W. Parke 2nd, D.B. Jones, L.O. Gentry.
Endogenous endophthalmitis among patients with candidemia.
Ophthalmology, 89 (1982), pp. 789-796
[195.]
R. Melamed, E. Leibovitz, O. Abramson, A. Levitas, N. Zucker, R. Gorodisher.
Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome).
Scand J Infect Dis, 32 (2000), pp. 86-89
[196.]
L. Aaron, A. Therby, J.P. Viard, R. Lahoulou, B. Dupont.
Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis.
Scand J Infect Dis, 35 (2003), pp. 351-352
[197.]
K. Westling, A. Thalme, I. Julander.
Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole.
Scand J Infect Dis, 37 (2005), pp. 310-311
[198.]
R. Rajendram, N.J. Alp, A.R. Mitchell, I.C. Bowler, J.C. Forfar.
Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement.
Clin Infect Dis, 40 (2005), pp. e72-e74
[199.]
W.J. Steinbach, J.R. Perfect, C.H. Cabell, et al.
A meta-analysis of medical versus surgical therapy for Candida endocarditis.
J Infect, 51 (2005), pp. 230-247
[200.]
T.J. Walsh, P.O. Whithcomb, S.G. Revankar, P.A. Pizzo.
Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia.
Cancer, 76 (1995), pp. 2357-2362
[201.]
J. Pachón, J.M. Cisneros, A.R. Collado-Romacho, et al.
Tratamiento de las infecciones fúngicas invasora.
Enferm Infecc Microbiol Clin, 24 (2006), pp. 254-263
[202.]
J.W. Bjerke, J.D. Meyers, R.A. Bowden.
Hepatosplenic candidiasis, a contraindication to marrow transplantation.
Blood, 84 (1994), pp. 2811-2814
[203.]
P.C. Gokhale, R.J. Barapatre, S.H. Advani, N.A. Kshirsagar, S.K. Pandya.
Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.
J Cancer Res Clin Oncol, 119 (1993), pp. 569-571
[204.]
E. Anaissie, G.P. Bodey, H. Kantarjian, et al.
Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.
Am J Med, 91 (1991), pp. 142-150
[205.]
C.A. Kauffman, S.F. Bradley, S.C. Ross, D.R. Weber.
Hepatosplenic candidiasis: successful treatment with fluconazole.
Am J Med, 91 (1991), pp. 137-141
[206.]
F. Sora, P. Chiusolo, N. Piccirillo, et al.
Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B.
Clin Infect Dis, 35 (2002), pp. 1135-1136
[207.]
A. Masood, S. Sallah.
Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment.
Leuk Research, 29 (2005), pp. 493-501
[208.]
J.H. Rex, J.E. Bennett, A.M. Sugar, et al.
Intravascular catheter exchange and duration of candidemia NIAID Mycoses Study Group and the Candidemia Study Group.
Clin Infect Dis, 21 (1995), pp. 994-996
[209.]
I. Raad, H. Hanna, M. Boktour, et al.
Management of central venous catheters in patients with cancer and candidemia.
Clin Infect Dis, 38 (2004), pp. 1119-1127
[210.]
B. Almirante, D. Rodríguez, B.J. Park, Barcelona Candidemia Project Study Group, et al.
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona Spain, from 2002 to 2003.
J Clin Microbiol, 43 (2005), pp. 1829-1835
[211.]
A.C. Pasqualotto, A.B. de Moraes, R.R. Zanini, L.C. Severo.
Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place.
Infect Control Hosp Epidemiol, 28 (2007), pp. 799-804
[212.]
D. Rodriguez, B.J. Park, B. Almirante, Barcelona Candidemia Project Study Group, et al.
Impact of early central venous catheter removal on outcome in patients with candidaemia.
Clin Microbiol Infect, 13 (2007), pp. 788-793
[213.]
C.Y. Liu, L.J. Huang, W.S. Wang, et al.
Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome.
J Infect, 58 (2009), pp. 154-160
[214.]
M. Nucci, E. Anaissie, R.F. Betts, et al.
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.
Clin Infect Dis, 51 (2010), pp. 295-303
[215.]
Empiric antifungal therapy in febrile granulocytopenic patients.
EORTC International Antimicrobial Therapy Cooperative Group.
Am J Med, 86 (1989), pp. 668-672
[216.]
P.A. Pizzo, K.J. Robichaud, F.A. Gill, F.G. Witebsky.
Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.
Am J Med, 72 (1982), pp. 101-111
[217.]
T.J. Walsh, R.W. Finberg, C. Arndt, et al.
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia National Institute of Allergy and Infectious Diseases Mycoses Study Group.
N Engl J Med, 340 (1999), pp. 764-771
[218.]
T.J. Walsh, P. Pappas, D.J. Winston, et al.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med, 346 (2002), pp. 225-234
[219.]
T.J. Walsh, H. Teppler, G.R. Donowitz, et al.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
N Engl J Med, 351 (2004), pp. 1391-1402
[220.]
J. Maertens, D. Deeren, D. Dierickx, K. Theunissen.
Preemptive antifungal therapy: still a way to go.
Curr Opin Infect Dis, 19 (2006), pp. 551-556
[221.]
J. Maertens, K. Theunissen, G. Verhoef, et al.
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Clin Infect Dis, 41 (2005), pp. 1242-1250
[222.]
Z. Odabasi, G. Mattiuzzi, E. Estey, et al.
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Clin Infect Dis, 39 (2004), pp. 199-205
[223.]
A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, et al.
Infectious Diseases Society of America Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.
Clin Infect Dis, 52 (2011),
[224.]
W.R. Jarvis.
Epidemiology of nosocomial fungal infections, with emphasis on Candida species.
Clin Infect Dis, 20 (1995), pp. 1526-1530
[225.]
J. Morgan, M.I. Meltzer, B.D. Plikaytis, et al.
Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.
Infect Control Hosp Epidemiol, 26 (2005), pp. 540-547
[226.]
K.W. Garey, M. Rege, M.P. Pai, et al.
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Clin Infect Dis, 43 (2006), pp. 25-31
[227.]
M. Morrell, V.J. Fraser, M.H. Kollef.
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.
Antimicrob Agents Chemother, 49 (2005), pp. 3640-3645
[228.]
N.I. Paphitou, L. Ostrosky-Zeichner, J.H. Rex.
Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials.
Med Mycol, 43 (2005), pp. 235-243
[229.]
L. Ostrosky-Zeichner, C. Sable, J. Sobel, et al.
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting.
Eur J Clin Microbiol Infect Dis, 26 (2007), pp. 271-276
[230.]
H. Dupont, A. Bourichon, C. Paugam-Burtz, J. Mantz, J.M. Desmonts.
Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?.
Crit Care Med, 31 (2003), pp. 752-757
[231.]
C. Leon, S. Ruiz-Santana, P. Saavedra, et al.
A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization.
Crit Care Med, 34 (2006), pp. 730-737
[232.]
R. Piarroux, F. Grenouillet, P. Balvay, et al.
Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients.
Crit Care Med, 32 (2004), pp. 2443-2449
[233.]
Y. Takesue, M. Kakehashi, H. Ohge, et al.
Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients.
World J Surg, 28 (2004), pp. 625-630
[234.]
M.S. Moreira-Oliveira, Y. Mikami, M. Miyaji, T. Imai, A.Z. Schreiber, M.L. Moretti.
Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 721-726
[235.]
T.J. Walsh, J.W. Lee, E. Roilides, P.A. Pizzo.
Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.
Curr Opin Oncol, 4 (1992), pp. 647-655
[236.]
E.J. Bow, M. Laverdiere, N. Lussier, C. Rotstein, M.S. Cheang, S. Ioannou.
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomizedcontrolled clinical trials.
Cancer, 94 (2002), pp. 3230-3246
[237.]
M.A. Slavin, B. Osborne, R. Adams, et al.
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study.
J Infect Dis, 171 (1995), pp. 1545-1552
[238.]
J.L. Goodman, D.J. Winston, R.A. Greenfield, et al.
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
N Engl J Med, 326 (1992), pp. 845-851
[239.]
M.L. MacMillan, J.L. Goodman, T.E. DeFor, D.J. Weisdorf.
Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy.
Am J Med, 112 (2002), pp. 369-379
[240.]
J.A. van Burik, V. Ratanatharathorn, D.E. Stepan, et al.
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
Clin Infect Dis, 39 (2004), pp. 1407-1416
[241.]
I. Oren, J.M. Rowe, H. Sprecher, et al.
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Bone Marrow Transplant, 38 (2006), pp. 127-134
[242.]
D.J. Winston, R.T. Maziarz, P.H. Chandrasekar, et al.
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial.
Ann Intern Med, 138 (2003), pp. 705-713
[243.]
J.R. Wingard, S.L. Carter, T.J. Walsh, et al.
Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients.
Blood, 110 (2007), pp. 55a
[244.]
A.J. Ullmann, J.H. Lipton, D.H. Vesole, et al.
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
N Engl J Med, 356 (2007), pp. 335-347
[245.]
O.A. Cornely, J. Maertens, D.J. Winston, et al.
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med, 356 (2007), pp. 348-359
[246.]
A. Glasmacher, A. Prentice, M. Gorschluter, et al.
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
J Clin Oncol, 21 (2003), pp. 4615-4626
[247.]
D.W. Kubiak, J.M. Bryar, A.M. McDonnell, J.O. Delgado-Flores, E. Mui, L.R. Baden, F.M. Marty.
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Clin Ther, 32 (2010), pp. 637-648
[248.]
K.C. Abbott, I. Hypolite, R.K. Poropatich, et al.
Hospitalizations for fungal infections after renal transplantation in the United States.
Transpl Infect Dis, 3 (2001), pp. 203-211
[249.]
N. Safdar, W.R. Slattery, V. Knasinski, et al.
Predictors and outcomes of candiduria in renal transplant recipients.
Clin Infect Dis, 40 (2005), pp. 1413-1421
[250.]
S. Husain, J. Tollemar, E.A. Dominguez, et al.
Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, casecontrolled study.
Transplantation, 75 (2003), pp. 12
[251.]
M. Cruciani, C. Mengoli, M. Malena, O. Bosco, G. Serpelloni, P. Grossi.
Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis.
Liver Transplantation, 12 (2006), pp. 850-858
[252.]
J.M. Rabkin, S.L. Oroloff, C.L. Corless, et al.
Association of fungal infection and increased mortality in liver transplant recipients.
Am J Surg, 179 (2000), pp. 426-430
[253.]
N. Singh, M.M. Wagener, I.R. Marino, T. Gayowski.
Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices.
Transplantation, 73 (2002), pp. 63-67
[254.]
E. Benedetti, A.C. Gruessner, C. Troppmann, et al.
Intraabdominal fungal infections after pancreas transplantation: incidence, treatment and outcome.
J Am Coll Surg, 183 (1996), pp. 307-316
[255.]
G. Michalak, A. Kwiatkowski, M. Bieniasz, et al.
Infectious complications after simultaneous pancreas-kidney transplantation.
Transplant Proc, 37 (2005), pp. 3560-3563
[256.]
P. Grossi, C. Farina, R. Fiocchi, D. Dalla Gasperina.
Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study.
Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients Transplantation, 70 (2000), pp. 112-116
[257.]
J.S. Dummer, N. Lazariashvilli, J. Barnes, M. Ninan, A.P. Milstone.
A survey of antifungal management in lung transplantation.
J Heart-Lung Transplant, 23 (2004), pp. 1376-1381
[258.]
R. Zaragoza, J. Pemán, M. Salavert, A. Viudes, A. Solé, I. Jarque, E. Monte, E. Romá, E. Cantón.
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?.
Ther Clin Risk Manag, 4 (2008), pp. 1261-1280
[259.]
A.F. Shorr, K. Chung, W.L. Jackson, P.E. Waterman, M.H. Kollef.
Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.
Crit Care Med, 33 (2005), pp. 1928-1935
[260.]
S.W. Lam, G.A. Eschenauer, P.L. Carver.
Evolving role of early antifungals in the adult intensive care unit.
Crit Care Med, 37 (2009), pp. 1580-1593
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
